



Driving innovation through intelligent automation

CSE : **TELI**

OTCQB : **TELIF**

FSE : **J4U**



Genentech



Corporate Presentation

June 2026

www.telescopeinnovations.com





Disclaimer

The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, accounting, investment, business, or legal advice, in any way whatsoever. The reader should consult with a lawyer, accountant, and other professionals in respect of contents hereof. Furthermore, the information in no way should be construed or interpreted as, or as a part of, an offering or solicitation of securities. Investors are advised to discuss any trading with a registered securities broker or personal finance professional prior to investing.

This Presentation includes and is based on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Factors that might cause or contribute to such differences include, but are not limited to, economic conditions globally, the impact of competition, political and economic developments in the countries and states in which the Company operates, and regulatory developments domestically and internationally. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "anticipates", "targets", "goals", "projects", "intends", "plans", "believes", "seeks", "estimates", variations of such words, and similar expressions. Important factors that could cause actual results to differ materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for the Company's businesses, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates, and such other factors as may be discussed from time to time. Although the Company believes that its expectations and the information in this Presentation were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Presentation. The Company is not making any representation or warranty, expressed or implied, as to the accuracy, reliability, or completeness of the information in the Presentation, and neither the Company nor any of its directors, officers, or employees will have any liability to the reader or any other persons resulting from the reader's use of the information in the Presentation. The Company undertakes no obligation to publicly update or revise any forward-looking information or statements in the Presentation. The reader should consult any further disclosures the Company may make in documents it files with the applicable securities regulators.





Telescope develops and deploys **Physical Artificial Intelligence** platforms which **accelerate innovation**

Telescope reduces R&D, manufacturing, and commercial deployment time and costs for the chemicals, pharmaceutical, and critical minerals industries



Design of Experiments

AI/ML-driven experiment design



Automation & Robotics

Modular robotic platforms for autonomous lab operations



Analytical Technology

Real-time inline analytics for process characterization



Artificial Intelligence

AI / ML-driven modelling, decision making, closed-loop optimization



CHEMICALS



PHARMA



CRITICAL MINERALS





Intelligence embodied in autonomous robotic systems — sensing, deciding, and acting in the physical world.


What is Physical AI?

Gartner's #1 Strategic Technology Trend for 2026

“Top 5 Future Trends That Got Everyone Talking in Pharma and BioTech This Year”, BioSpace Insights 2025

“Top 5 Future Trends in the Pharmaceutical Engineering”, Pharmaceutical Engineering 2025

“Top 5 Industrial Trends in 2025”, DelaControl





Self-Driving Labs: Physical AI for Chemical Process R&D

A Self-Driving Lab (SDL) integrates robotics, inline analytics, and machine learning to run multiple experiments in a continuous, autonomous workflow.



Richer, more **reliable data** accurately feeds AI models & digital twins



24/7 operation adds **76 hours per week** outside regular business hours



Better return on deployed capital:
40x energy, 4x time, 6x space efficiency¹



More efficient R&D **reduces time-to-market**, increases active patent life for new medicines



Reduced costs enable access to personalized medicines and **niche markets**


¹From Data-Rich Experimentation to Self-Driving Labs: Advancing Process Chemistry at Pfizer, SmartLab Exchange, Philadelphia, April 2026





The Impact of Physical AI in Pharmaceutical Industry

AI-guided decision making, automated experiments, and automatic analysis are reducing costs and accelerating the time from lab to market by 10 – 50x and increasing the commercial monetization under patent by an additional 1-2 years



¹ Management estimates





Global Demand for Lab Innovation

Major spending into intelligent automation to accelerate innovation

Governments around the world are incentivizing major new investments to resolve some of the world's most difficult challenges in health, energy, and sustainability

+

Conventional strategies are not meeting the required pace development in chemistry and materials science

=

Telescope provides intelligent automation tools to increase research throughput and quality – driving greater returns for R&D investments



Chemicals Industry

\$42B

Global R&D investment in the chemicals sector in Process R&D is 20% of Pharma



Pharmaceutical Industry

\$145B

Process Research & Development investment of top 20 pharmaceutical companies in 2026²



Clean Energy Industry

\$2T

Global R&D investment in the clean energy sector in 2023³

¹ Deloitte: 2024 Chemical Industry Outlook (2024)

² Deloitte: Annual Pharmaceutical Innovation Report (2024)

³ IEA: World Energy Investment (2024)






The Telescope Business Model

A scalable, three-pronged revenue generation model

A decades-long foundation of successful collaboration between our world class team and industry-leading customers



Product Revenue – DirectInject-LC™

An intelligent, automated chemical analysis tool...GPS for Chemistry & Process Development

DirectInject-LC™ **accelerates** chemistry research & **reduces development costs**.

Accelerating research through intelligent automation



Recurring Revenue

Accessories, services, and software licenses provide continued revenue beyond initial product sale



Platform Technology

Direct Inject provides a platform for expansion of TELI's current development pipeline of products and third-party tool integration to capture additional analytics markets



Product Pipeline

Telescope has four additional DirectInject intelligent automation products in the pipeline to service additional lab automation needs



DIRECTINJECT - LC™




Already adopted by **15 of the top 20** pharmaceutical companies in the world

RANKED BY REVENUE



Global Distribution Strategy

Leveraging international distribution partners to **accelerate the adoption of intelligent automation**



Mettler Toledo's incentives are intertwined with Telescope's success

Recurring Revenues

Telescope's current and future products require accessories, service, and software maintenance, which provide revenue beyond initial product sale

Customer Engagement

Telescope has intimate partnerships with end users while Mettler Toledo has relationships and a large install base with key customers globally

Portfolio Refresh

The Telescope product pipeline energizes Mettler Toledo's product mix, enabling Mettler Toledo to address emerging needs in the instrumentation sector

Nimble Development Partner

Telescope's flexibility, infrastructure, and established track record of rapidly innovating new products allow for agile response to evolving market conditions



Product Revenue – Self-Driving Labs

Telescope is developing self-driving labs that leverage robotics, analytical technology, and AI control software to rapidly optimize experiments

Revolutionizing R&D in process chemistry



Accelerated Time-to-Market

Enables the potential to bring new products to market on a significantly reduced development timeline and cost



Increased Competitiveness

Higher R&D efficiency enables companies to re-shore supply chains, manufacturing, and IP development



Major Global Investments

Companies are making major investments into intelligent lab automation to accelerate R&D and keep pace with competitors



SELF-DRIVING LABS

Accelerating the transition of novel chemicals, materials, or processes from discovery to large-scale commercial deployment




Telescope has signed a multi-year, master collaborative research agreement with Pfizer to accelerate R&D through development of self-driving labs in July 2024.

Pfizer has purchased two Telescope SDL platforms





What the Experts Say...



“AI is only as good as the chemistry it's based on, and Telescope's chemistry is superlative. It's so exciting for me to participate in making Self-Driving Labs a reality with Jason Hein and his extraordinary team”

PROF. BARRY K SHARPLESS

Two-Time Nobel Prize Winner in Chemistry (2001, 2022)
Telescope Innovations Senior Scientific Advisor




Telescope Innovations team with Prof. Barry Sharpless at Self-Driving Lab Installation & Training for the Korean Pharmaceutical & Biopharma Manufacturers Association (300 Member Companies), AI focused R&D Center in Seoul, December 2025

Sounds nice... but, is it real?





Customers Use Telescope's Self-Driving Labs Platform (Physical AI) Platform to Better Develop New Mfg Processes







Telescope Also Uses In-House Physical AI Platform to Develop New Intellectual Property

Automation and online analysis tools accelerate chemical manufacturing processes.

Telescope Innovations Physical AI Tools



Our experience shows that automation can have meaningful results towards improving speed, accuracy, and cost of chemical testing and create monetization opportunities through non-exclusive licensing of Intellectual Property


Enabling Technology to develop Manufacturing Processes for High Value Specialty Materials such as Pharmaceuticals, Specialty Chemicals, High Value Battery Content like **Li₂S, Lithium Di-Hydrogen Phosphate, Anhydrous LiCl, etc.**





Intellectual Property Licensing – Case Study

Telescope has developed and is licensing a process for purification of Battery Grade Lithium Carbonate using In-House Physical AI Platform to drive Purification Process Optimization





Telescope Uses In-House Physical AI Platform to Develop New Manufacturing Process Intellectual Property

OUR LITHIUM TECHNOLOGY PORTFOLIO

Lithium carbonate purification

Battery-grade using pharmaceutical-style recrystallization

ReCRFT™

US patent app. 63/606,069,
patent pending
[Press release](#)

Lithium sulfide manufacturing

Low-cost, ambient temperature lithium sulfide production

DualPure™

US patent app. 63/584,062
[Press release](#)

Battery recycling

Reagent-free transition metal separations from battery recycling feeds



Proof of Concept
Trade secret
[Press release](#)



Global Customer & Partner Network

Strong partnerships cultivated over 30+ years with global enterprises accelerate distribution, development, and R&D funding



Contract Research Clients & Product Development Partners

Contract research client or distribution and product development partners



Pharmaceutical Partners

Customers and development partners



Funding & Academic Partners

Non-dilutive funding providers or R&D support





World Class Executive Team



Prof. Jason Hein
CTO & Director

Leads one of the largest academic chemistry research groups in Canada. Has authored 90+ peer-reviewed articles amassing over 4,000 citations. Directed the development of the DirectInject-LC™ platform that is the flagship product for Telescope.



Dr. Barry Sharpless
Senior Advisor

2-time winner of the Nobel Prize in Chemistry. His work has been described as "the most important discovery in the field of synthesis during the past few decades."



Henry Dubina
CEO & Chairman

35+ years experience in General Management in the Scientific Instrument Industry. As President and Global Head of Mettler-Toledo AutoChem, he directed the development of the business from inception to the global market leader for enabling tools, software and services for biopharmaceutical and chemical process development.



Vaso Vlachos
COO

Ms. Vlachos is a proven leader with over 20 years of experience managing automation and analytical technology offerings for the biopharmaceutical and chemical industries. Her background spans sales & marketing, operations, quality, and innovation management. Most recently, she was the Global Head of Mettler-Toledo AutoChem's Real-Time Analytics ("RTA") business



John Kirincic
CFO

20+ years of executive level experience in leading and growing companies through financial and operating functions. Deep corporate finance background working with growth-oriented companies in direct roles and through buy-side investment capital firms building value for shareholders.



Dr. Andy Robinson, Director

An accomplished scientist with 20+ years experience. Andy has held executive and board positions with a range of public and private companies. He is the President, COO & Director of Standard Lithium, a company leveraging unique process chemistry to build the first American commercial lithium project in over 50 years.

Robert Mintak, Director

20+ years experience in corporate management in a wide range of private and public companies with a specific emphasis on strategic development, corporate governance, and long-term creation of shareholder value. As the CEO of Standard Lithium, he has led the company to its position among the 50 best performers on the OTCQX market.

Ali Pejman, Director

20+ years experience as an Investment Banker having advised over \$25 Billion in M&A transactions and \$3 Billion in equity financings. He is currently Managing Partner at Fort Capital, a boutique investment bank. Mr. Pejman is an active angel investor and Associate of the Creative Destruction Labs, with current and prior Board positions on Science World, Vancouver Transit Police, and Vancouver/UBC General Hospital.





A Specialized Growth Team

Our management team combines internationally-recognized science acumen and a track record of value creation

Scientific Achievements

2
Nobel Prizes

34
patents

450+
academic publications

SCIENCE ACUMEN



VALUE CREATION

Values at Exit (USD)

Value Creation History

Grew and sold provider of analytical instrumentation for particle and materials characterization **\$215MM**

Grew and sold nuclear magnetic resonance (NMR) spectroscopy start-up business **\$15MM**

Grew from startup to current market cap as global market leader for providing automated process chemistry R&D equipment **\$1.0B¹**

Managed wearable health device manufacturer to exit after growing sales to over USD\$10MM **\$125MM**


Managed traffic control company while growing sales to over USD\$200MM **\$300MM**

Grew and sold asset management firm to over USD\$40MM in revenue **\$60MM**






Telescope's strong revenue growth is driven by market development and new product deployment



All figures in CAD

Revenue



Key Focus: Organizational Development Headcount Investment Investor Awareness

¹ Management estimates based on internal projections





Capital Structure

Telescope leverages AI, robotics, and advanced data analysis to make research faster, more precise, and more innovative

A Globally-Scalable Intelligent Automation Platform

Telescope's award-winning technical team has a proven track record supported by large multinational partners to develop innovative products and know-how that meet unmet commercial demand

Impending Growth Inflection

Expanded commercial product portfolio, future licensing of IP, and scaled distribution infrastructure define a new era of Telescope that pairs commercial success with continued product development

Capital Efficient Development

Contract research revenue, grants, and pre-purchase orders provide an array of non-dilutive funding sources used to fund the development of high-upside product and IP licensing portfolio

Share Capitalization

Dollar figures in CAD

Shares Outstanding	MM	80.8
<i>Held by Directors/Officers</i>	%	18%
Share Price MAY 20th, 2026		C\$0.80

Market Cap	MM	C\$65
------------	----	-------

Options	Ave Price \$0.43	MM	7.7
---------	------------------	----	-----

Fully Diluted Market Cap	MM	C\$71
--------------------------	----	-------

C\$6.5M in Capital Raised - October '25

**C\$3.36M Government Conditional Funding to
develop Advanced Lithium Processing
Technology - November '25**





Why Invest in Telescope Innovations...?

Physical AI Leadership

Self-Driving Lab platform at the nexus of Gartner's #1 trend for 2026 and \$49.7B market

Blue Chip Validation through Key Established Relationships

Pfizer, Mettler Toledo, and 15 of the top 20 pharma companies as customers and partners

Multiple Revenue Streams

Product sales, contract R&D, and IP licensing drive diversified, capital-efficient growth

World Class Team, Experienced Leadership

2-time Nobel Prize winner advisor, \$1.7B+ in value creation history, and deep domain expertise

Clean Energy Upside

Patented lithium technologies with CAD\$3.6M+ government funding for solid-state battery materials

Investors@telescopeinn.com | www.telescopeinnovations.com





TELESCOPE

INNOVATIONS

Driving innovation through intelligent automation

CSE : **TELI**

OTCQB : **TELIF**

FSE : **J4U**



Contact

Investors@telescopeinn.com

www.telescopeinnovations.com

